Pregabalin Prescription for Neuropathic Pain and Fibromyalgia: A Descriptive Study Using Administrative Database in Japan.
Pregabalin Prescription for Neuropathic Pain and Fibromyalgia: A Descriptive Study Using Administrative Database in Japan.
复制标题
DOI：
10.1155/2018/2786151
复制
发表时间：
2018
影响因子：
2.9
通讯作者：
Kawakami K
中科院分区：
文献类型：
--
作者：
Hirakata M;Yoshida S;Tanaka-Mizuno S;Kuwauchi A;Kawakami K
在日本，评估新处方普瑞巴林治疗神经性疼痛和纤维肌痛的患者的剂量、特征和共处方镇痛药。 基于Medical Data Vision数据库中的医疗和处方信息，我们分析了2010年7月1日至2013年12月31日期间新处方普瑞巴林的患者的初始和最大日剂量、处方周期、共处方镇痛药和神经性疼痛相关疾病。 在此期间，共有45，331例患者（平均年龄66.8岁，48.7%为男性）接受了新处方的普瑞巴林。平均初始日剂量和最大日剂量分别为97.3 mg和127.8 mg，并逐年下降。处方持续时间为111.9（平均）和53（中位）天，常用的共处方镇痛药包括NSAID、阿片类药物和Neurotropin®。大约一半的患者患有脊柱疾病。 在日本，在研究期间，新处方普瑞巴林使用者的数量增加，但普瑞巴林上市后，初始和最大日剂量逐年下降。日本的最大日剂量低于美国和欧洲报告的剂量。这些差异可能与患者的年龄和身体状况以及对可能的不良事件的焦虑有关。
To assess dose, characteristics, and coprescribed analgesics in patients newly prescribed pregabalin for neuropathic pain and fibromyalgia in Japan. Based on the medical and prescription information present in the Medical Data Vision database, we analyzed the initial and maximum daily doses, prescription period, coprescribed analgesics, and neuropathic pain-related disorders of patients newly prescribed pregabalin between 01 July 2010 and 31 December 2013. A total of 45,331 patients (mean age 66.8 years, 48.7% men) were newly prescribed pregabalin during this period. The mean initial and maximum daily doses were 97.3 mg and 127.8 mg, respectively, and decreased yearly. The duration of the prescription period was 111.9 (mean) and 53 (median) days, and the frequently coprescribed analgesics included NSAIDs, opioids, and Neurotropin®. About one half of the patients had spinal disorders. In Japan during the period examined, the number of newly prescribed pregabalin users increased, but the initial and maximum daily doses decreased yearly after pregabalin went on the market. The maximum daily dose in Japan was lower than those reported in the USA and Europe. These differences might be associated with patient age and physical status and with anxiety about possible adverse events.
登录
查看更多内容
影响因子：
1
作者：
Tanaka S;Seto K;Kawakami K
通讯作者：
Kawakami K
影响因子：
16.2
作者：
Freeman R;Durso-Decruz E;Emir B
通讯作者：
Emir B
影响因子：
2
作者：
Chung, Jae Hoon;Kim, Shin Ah;Moon, Hong Sang
通讯作者：
Moon, Hong Sang
影响因子：
5.1
作者：
Attal, N.;Cruccu, G.;Nurmikko, T.
通讯作者：
Nurmikko, T.
影响因子：
3.5
作者：
Satoh, J.;Yagihashi, S.;Shoji, S.
通讯作者：
Shoji, S.